Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement

Hidetoshi Hayashi, Isamu Okamoto, Hideharu Kimura, Kazuko Sakai, Yasumasa Nishimura, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively examined 37 patients with locally advanced NSCLC treated with definitive thoracic radiotherapy (TRT). Characteristics were compared among patients classified positive for EGFR mutations, EML4-ALK rearrangement, or patients who were double-negative for these changes. Results: We identified 11 (29.7%) patients with EGFR mutations and 3 (8.1%) with an EML4-ALK rearrangement. Progression-free survival of patients with EGFR mutation-positive NSCLC was similar to the one of those with double-negative disease (13.1 and 18.6 months). The incidence of local recurrence was higher in EGFR mutation-positive patients with NSCLC than in double-negative NSCLC. Conclusion: EGFR mutations and the EML4-ALK rearrangements were detected in substantial proportions of patients with locally advanced NSCLC. The efficacy of TRT was limited in patients with EGFR mutations.

Original languageEnglish
Pages (from-to)4533-4538
Number of pages6
JournalAnticancer research
Volume32
Issue number10
Publication statusPublished - Oct 1 2012

Fingerprint

erbB-1 Genes
Radiotherapy
Thorax
Non-Small Cell Lung Carcinoma
Mutation
MAP4
anaplastic lymphoma kinase
Gene Fusion
Disease-Free Survival
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hayashi, H., Okamoto, I., Kimura, H., Sakai, K., Nishimura, Y., Nishio, K., & Nakagawa, K. (2012). Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement. Anticancer research, 32(10), 4533-4538.

Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement. / Hayashi, Hidetoshi; Okamoto, Isamu; Kimura, Hideharu; Sakai, Kazuko; Nishimura, Yasumasa; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Anticancer research, Vol. 32, No. 10, 01.10.2012, p. 4533-4538.

Research output: Contribution to journalArticle

Hayashi, H, Okamoto, I, Kimura, H, Sakai, K, Nishimura, Y, Nishio, K & Nakagawa, K 2012, 'Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement', Anticancer research, vol. 32, no. 10, pp. 4533-4538.
Hayashi, Hidetoshi ; Okamoto, Isamu ; Kimura, Hideharu ; Sakai, Kazuko ; Nishimura, Yasumasa ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement. In: Anticancer research. 2012 ; Vol. 32, No. 10. pp. 4533-4538.
@article{b800a8529f4a404cbd24f3fc9c9ba8ed,
title = "Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement",
abstract = "Background: Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively examined 37 patients with locally advanced NSCLC treated with definitive thoracic radiotherapy (TRT). Characteristics were compared among patients classified positive for EGFR mutations, EML4-ALK rearrangement, or patients who were double-negative for these changes. Results: We identified 11 (29.7{\%}) patients with EGFR mutations and 3 (8.1{\%}) with an EML4-ALK rearrangement. Progression-free survival of patients with EGFR mutation-positive NSCLC was similar to the one of those with double-negative disease (13.1 and 18.6 months). The incidence of local recurrence was higher in EGFR mutation-positive patients with NSCLC than in double-negative NSCLC. Conclusion: EGFR mutations and the EML4-ALK rearrangements were detected in substantial proportions of patients with locally advanced NSCLC. The efficacy of TRT was limited in patients with EGFR mutations.",
author = "Hidetoshi Hayashi and Isamu Okamoto and Hideharu Kimura and Kazuko Sakai and Yasumasa Nishimura and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2012",
month = "10",
day = "1",
language = "English",
volume = "32",
pages = "4533--4538",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement

AU - Hayashi, Hidetoshi

AU - Okamoto, Isamu

AU - Kimura, Hideharu

AU - Sakai, Kazuko

AU - Nishimura, Yasumasa

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background: Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively examined 37 patients with locally advanced NSCLC treated with definitive thoracic radiotherapy (TRT). Characteristics were compared among patients classified positive for EGFR mutations, EML4-ALK rearrangement, or patients who were double-negative for these changes. Results: We identified 11 (29.7%) patients with EGFR mutations and 3 (8.1%) with an EML4-ALK rearrangement. Progression-free survival of patients with EGFR mutation-positive NSCLC was similar to the one of those with double-negative disease (13.1 and 18.6 months). The incidence of local recurrence was higher in EGFR mutation-positive patients with NSCLC than in double-negative NSCLC. Conclusion: EGFR mutations and the EML4-ALK rearrangements were detected in substantial proportions of patients with locally advanced NSCLC. The efficacy of TRT was limited in patients with EGFR mutations.

AB - Background: Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively examined 37 patients with locally advanced NSCLC treated with definitive thoracic radiotherapy (TRT). Characteristics were compared among patients classified positive for EGFR mutations, EML4-ALK rearrangement, or patients who were double-negative for these changes. Results: We identified 11 (29.7%) patients with EGFR mutations and 3 (8.1%) with an EML4-ALK rearrangement. Progression-free survival of patients with EGFR mutation-positive NSCLC was similar to the one of those with double-negative disease (13.1 and 18.6 months). The incidence of local recurrence was higher in EGFR mutation-positive patients with NSCLC than in double-negative NSCLC. Conclusion: EGFR mutations and the EML4-ALK rearrangements were detected in substantial proportions of patients with locally advanced NSCLC. The efficacy of TRT was limited in patients with EGFR mutations.

UR - http://www.scopus.com/inward/record.url?scp=84867786487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867786487&partnerID=8YFLogxK

M3 - Article

C2 - 23060582

AN - SCOPUS:84867786487

VL - 32

SP - 4533

EP - 4538

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -